A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor.
about
Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegansReversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregationAggresome formation and neurodegenerative diseases: therapeutic implicationsIdentification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model systemHigh throughput screening for neurodegeneration and complex disease phenotypes.Drug screening to identify suppressors of GFAP expressionComposite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions.Functional drug screening assay reveals potential glioma therapeutics.Enhancing the anticancer properties of cardiac glycosides by neoglycorandomizationGetting folded: chaperone proteins in muscle development, maintenance and disease.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.A cell-based fascin bioassay identifies compounds with potential anti-metastasis or cognition-enhancing functions.Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform.Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.The structure and allosteric regulation of mammalian glutamate dehydrogenase.Proteasome Inhibition Contributed to the Cytotoxicity of Arenobufagin after Its Binding with Na, K-ATPase in Human Cervical Carcinoma HeLa Cells.An α2-Na/K ATPase/α-adducin complex in astrocytes triggers non-cell autonomous neurodegenerationCelastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response.High throughput screening reveals several new classes of glutamate dehydrogenase inhibitorsMitochondrial abnormalities in spinal and bulbar muscular atrophyTannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndromeNeurobiological applications of small molecule screening.Perspectives on gene therapy in myotonic dystrophy type 1.A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells.Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts.In vitro and in vivo effects of suloctidil on growth and biofilm formation of the opportunistic fungus Candida albicans.Candida albicans-derived mannoproteins activate NF-κB in reporter cells expressing TLR4, MD2 and CD14.
P2860
Q21144448-84543B6A-0B2A-4F16-819A-E3F879EA31A2Q24799882-833E3F3D-8E0C-418E-822A-D273F3F2A763Q28265926-0C2E2DB3-B270-4AED-AFA8-8284B2868AE1Q28477163-A767D90F-496C-4CEA-92D8-D28959ECD680Q33323473-D64DDF60-DBC3-423C-9927-BC438431A395Q33600870-4B3BA05A-F91A-4C80-86A2-D328D166D98AQ33617333-A37CE960-8AA6-4F45-AB15-A0944AED7EFCQ33780121-78DEF7B6-7479-4372-A36E-8F4643FEB9BEQ33933859-7B052C94-F9F1-4EF8-9B87-ADE78AF9BF82Q34055646-FD83BA21-E5D8-4A1F-B05C-E5973B5AEA28Q34066654-EBDF7A8B-BC05-4399-9773-2450F4E81CF5Q34392217-51A3D3C7-D3A0-4AA6-B7ED-5DC0F71835E1Q34691557-AD4E3D82-0FED-4229-A40F-30ED579DACF0Q35419466-57DCD8A3-F16B-4B5A-B6AE-D052CEE16EF5Q35803204-B84243C4-0C29-4BBA-A88C-B2E0539F2440Q36080090-4F456C36-22EE-4D26-8B85-751FA83D609FQ36436446-64BFAB1B-1EB5-4428-819D-0FED29BD123BQ36488831-32077939-8C3A-41D8-8BB4-B867C34CFF97Q36736887-56A1CC65-2C22-45AA-90A7-4C6DA3832C67Q37102121-ED67F9B3-06FB-4EC7-99F7-C91BAEE57AD9Q37128363-ACFC3AD5-B64E-4CDF-ADAE-0EC761C62AAFQ37151213-0816DE72-0E0D-484F-883F-5F65BEDF2A15Q37831858-19C24C58-886B-43AD-BDD0-7298894A8F20Q38691998-EDDE11F8-4101-4D2D-A3BE-B8E33D7CE18FQ38792714-06A6FA3C-817A-4290-AB94-FDE891E6391EQ42378397-2C8FEC73-50D2-4351-A7CC-45DB94AC1EA4Q47242917-AF13B786-3507-494D-AA31-17F73A17DFC3
P2860
A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A screen for drugs that protec ...... ne-expanded androgen receptor.
@en
A screen for drugs that protec ...... ne-expanded androgen receptor.
@nl
type
label
A screen for drugs that protec ...... ne-expanded androgen receptor.
@en
A screen for drugs that protec ...... ne-expanded androgen receptor.
@nl
prefLabel
A screen for drugs that protec ...... ne-expanded androgen receptor.
@en
A screen for drugs that protec ...... ne-expanded androgen receptor.
@nl
P2093
P356
P1476
A screen for drugs that protec ...... ine-expanded androgen receptor
@en
P2093
Benjamin R Roman
Federica Piccioni
Kenneth H Fischbeck
P304
P356
10.1093/HMG/DDH045
P577
2004-01-06T00:00:00Z